Skip to main content

Epigenomics Closes 21M Series C Round

NEW YORK, April 3 - Epigenomics has closed a Series C round of financing worth €21 million, or around $ 22.5 million, the company said today.


This third round brings to €56 million the total capital raised by the DNA methylation firm since it was created in 1998. Epigenomics said it will use the funds to further develop its diagnostic products in cancer, as well as its pharmacodiagnostic and research products.


New investor the Wellcome Trust Limited and all existing VC investors--3i Group, Abingworth, Deutsche Venture Capital DVC, MPM Capital, and tbg--participated in the round.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.